{"id":83798,"date":"2019-10-14T03:48:37","date_gmt":"2019-10-14T03:48:37","guid":{"rendered":"https:\/\/www.edristi.in\/?p=83798"},"modified":"2019-10-14T03:48:39","modified_gmt":"2019-10-14T03:48:39","slug":"indias-1st-large-scale-trial-of-two-new-tb-vaccines-launched","status":"publish","type":"post","link":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/indias-1st-large-scale-trial-of-two-new-tb-vaccines-launched\/","title":{"rendered":"India\u2019s 1st large-scale trial of two new TB vaccines launched"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Question: Recently Indian Council of Medical Research (ICMR) launched India\u2019s first large-scale trial for two new vaccines, named IMMUVAC and VPM1002 to fight against:<br> (a) TB<br> (b) HIV<br> (c) Japanese Encephalitis<br> (d) Ebola<br> Answer: (a)<br> Related facts:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Indian Council of Medical Research (ICMR) launched India\u2019s first large-scale trial for two new tuberculosis (TB) vaccines named IMMUVAC and VPM1002.<\/li><li>These vaccines aim to prevent infection (pre-exposure) or prevent primary progression or reactivation of latent TB infection (post-exposure). <\/li><li>Both vaccines have been manufactured by Indian pharmaceutical companies.<\/li><li>Immuvac, which is also known as Mycobacterium Indicus Pranii (MIP), has been manufactured by Ahmedabad based Cadila Pharmaceuticals.<\/li><li>Another vaccine VPM1002 is manufactured by Serum institute of India, located in Pune, Maharashtra.<\/li><li>It should be known that until now Bacille Calmette-Guerin (BCG) vaccine is widely used in routine Expanded Programme of Immunization (EPI) across the world.<\/li><li>Need for the new vaccine is being felt since last many years as over a century old BCG vaccine, for this purpose, provides poor protection against pulmonary disease in adolescents  and adults.<\/li><li>Trial of these vaccines is being carried out upon more than 12,000 healthy household contacts of newly diagnosed TB patients from across six states including Delhi, Maharashtra, Odisha and Karnataka.<\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Links:<br><a href=\"https:\/\/www.financialexpress.com\/lifestyle\/health\/first-time-ever-indias-to-conduct-its-biggest-tuberculosis-preventive-trial-with-two-new-vaccines\/1662803\/\">https:\/\/www.financialexpress.com\/lifestyle\/health\/first-time-ever-indias-to-conduct-its-biggest-tuberculosis-preventive-trial-with-two-new-vaccines\/1662803\/<br><\/a><a href=\"https:\/\/www.cdc.gov\/tb\/topic\/basics\/vaccines.htm\">https:\/\/www.cdc.gov\/tb\/topic\/basics\/vaccines.htm<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Question: Recently Indian Council of Medical Research (ICMR) launched India\u2019s first large-scale trial for two new vaccines, named IMMUVAC and VPM1002 to fight against: (a) TB (b) HIV (c) Japanese Encephalitis (d) Ebola Answer: (a) Related facts: Indian Council of Medical Research (ICMR) launched India\u2019s first large-scale trial for two new tuberculosis (TB) vaccines named [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":83799,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[1131],"tags":[2377],"class_list":["post-83798","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dssn","tag-defensescience-short-notes"],"jetpack_publicize_connections":[],"jetpack_shortlink":"https:\/\/wp.me\/phvHKS-lNA","jetpack_likes_enabled":true,"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/i0.wp.com\/www.edristi.in\/wp-content\/uploads\/2019\/10\/scienceIndia.jpg?fit=250%2C173&ssl=1","_links":{"self":[{"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/posts\/83798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/comments?post=83798"}],"version-history":[{"count":0,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/posts\/83798\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/media\/83799"}],"wp:attachment":[{"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/media?parent=83798"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/categories?post=83798"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/tags?post=83798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}